Targeting PI3Kδ in cancer: a setback or the end

Journal article

Open access

Peer reviewed

Zhonglin Hao, Susanne Arnold and Jill Kolesar

Frontiers in oncology, Vol.15, 1614882

11/03/2025

DOI: 10.3389/fonc.2025.1614882

PMCID: PMC12620252

PMID: 41256311

Files and links (1)

url

https://doi.org/10.3389/fonc.2025.1614882View

Published (Version of record) Open Access

no abstract

phosphatidylinositol 3-kinase delta inhibitors

indolent lymphoma

adverse events

intermittent dosing

solid tumor immunotherapy

Title: Subtitle: Targeting PI3Kδ in cancer: a setback or the end
Creators: Zhonglin Hao
Susanne Arnold
Jill Kolesar
Resource Type: Journal article
Publication Details: Frontiers in oncology, Vol.15, 1614882
DOI: 10.3389/fonc.2025.1614882
PMID: 41256311
PMCID: PMC12620252
NLM abbreviation: Front Oncol
ISSN: 2234-943X
eISSN: 2234-943X
Publisher: FRONTIERS MEDIA SA
Grant note: National Cancer Institute
The author(s) declare that no financial support was received for the research and/or publication of this article.
Language: English
Date published: 11/03/2025
Academic Unit: Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics; Obstetrics and Gynecology
Record Identifier: 9985024139202771

25 Record Views